Hopp til innhold
NHI.no
Annonse

Magesekkreft: Bivirkninger/komplikasjoner

Innhold i artikkelen

De fleste går ned i vekt etter operasjon, men de kan senere få vekten opp igjen. Ved fjerning av hele magesekken (total gastrektomi) kan det de første månedene etter operasjonen forekomme "dumping syndrom" (for rask tømming av magesekken etter måltid).

Annonse

Symptomer på "dumping syndrom"

Symptomene kommer ofte 10-15 minutter etter at et måltid er inntatt. Det opptrer i form av kvalme, oppkast, skjelving, kaldsvetting, kramper, rask puls, slapphet og noen ganger diaré.

Råd ved "dumping syndrom"

  • Spis små måltider, hver andre til tredje time
  • Innta proteinrik mat
  • Drikk mellom måltidene
  • Vær forsiktig med sukker
  • Slapp av etter måltidene, ligg gjerne ned og hvil en stund

Etter at hele magesekken er fjernet, kan en del pasienter oppleve at en del matvarer som man før tålte, ikke passer så bra lenger. Dette er noe hver enkelt må finne ut av og prøve seg frem til over tid.

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Ventrikkelkreft . Referanselisten for dette dokumentet vises nedenfor

  1. Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av kreft i magesekken (ventrikkelkreft). 15.06.2018. helsedirektoratet.no
  2. Murphy MB. Stomach cancer. BMJ Best Practice, last updated 25 May, 2021.
  3. Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer. Lancet. 2020;396(10251):635-648. PubMed
  4. Kreftregisteret. Cancer in Norway 2019. Oslo: Kreftregisteret, 2020. www.kreftregisteret.no. www.kreftregisteret.no
  5. Kamangar F, Dawsey SM, Blaser MJ et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with helicobacter pylori seropositivity. J Natl Cancer Inst 2006; 98: 1445-52. PubMed
  6. Fukase K, Kato M, Kikuchi S et al. and for the Japan Gast Study Group. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392-7. PubMed
  7. Hatakeyama M. Malignant Helicobacter pylori-associated diseases: gastric cancer and MALT lymphoma. Adv Exp Med Biol. 2019; 1149: 135-149. PubMed
  8. Fock KM, Talley NJ, Moayyedi P et al. Asia Pacific Consensus Guideline on gastric cancer prevention. J Gastroenterol Hepatol 2008; 23: 351-65. PubMed
  9. Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018; 378: 1085-1095. PubMed
  10. Lee Y-C, Chiang T-H, Chou C-K, et al. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: a Systematic Review and Meta-analysis. Gastroenterology. 2016 Jan 30 . pmid: 26836587 PubMed
  11. Bartley AN, Washington MK, Colasacco C et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 2017; 35(4): 446-64. pmid:28129524 PubMed
  12. Stapley S, Peters TJ, Neal RD et al. The risk of oesophago-gastric cancer in symptomatic patients in primary care: a large case-control study using electronic records. Br J Cancer. 2013;108:25-31. PMID: 23257895. PubMed
  13. Hartgrink HH, Jansen EPM, van Grieken NCT, van de Velde CJH. Gastric cancer. Lancet 2009;374:477-90. PubMed
  14. Wan QY, Wu XT, Li N, Du L, Zhou Y. Long-term proton pump inhibitors use and risk of gastric cancer: a meta-analysis of 926 386 participants. Gut. 2019;68(4):762-764. doi:10.1136/gutjnl-2018-316416 DOI
  15. Jiang K, Jiang X, Wen Y, Liao L, Liu FB. Relationship between long-term use of proton pump inhibitors and risk of gastric cancer: A systematic analysis. J Gastroenterol Hepatol. 2019;34(11):1898-1905. doi:10.1111/jgh.14759 DOI
  16. Abrahami D, McDonald EG, Schnitzer ME, et al. Proton pump inhibitors and risk of gastric cancer: population-based cohort study. Gut 2022; 71: 16-24. pmid:34226290 PubMed
  17. Smyth E, Schöder H, Strong VE, et al. A prospective evaluation of the utility of 2-deoxy-2-(18) Ffluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. Cancer. 2012;118(22):5481-5488. PubMed
  18. Talley NJ. Is it time to screen and treat H pylori to prevent gastric cancer?. Lancet 2008; 372: 350-2. PubMed
  19. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20. pmid: 16822992 PubMed
  20. Ohtani H, Tamamori Y, Noguchi K, et al. A meta-analysis of randomized controlled trials that compared laparoscopy-assisted and open distal gastrectomy for early gastric cancer. J Gastrointest Surg 2010;14:958-964. PubMed
  21. Mamon H, Enzinger PC. Adjuvant and neoadjuvant treatment of gastric cancer. UpToDate, last updated Jan 18, 2019. UpToDate
  22. Keishiro Aoyagi, Kikuo Kouhuji, Junya Kizaki et al. Molecular targeting to treat gastric cancer. World J Gastroenterol 2014; 20: 13741-55. pmid:25320512 PubMed
  23. Ohtsu A1, Shah MA, Van Cutsem E et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29: 3968-76. pmid:21844504 PubMed
  24. Heiss MM1, Murawa P, Koralewski P et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 2010; 127: 2209-21. pmid:20473913 PubMed
  25. Mabe K, Takahashi M, Oizumi H, et al. Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer?. World J Gastroenterol 2009; 15: 4290-7. PubMed
Annonse
Annonse